In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, a division of Real Chemistry, explains how weekly data from 300 million patients can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes.

Machine learning and artificial intelligence have emerged as key technologies for stitching together medical events and then predicting a diagnosis, even for conditions that are so rare no ICD-10 code exists. Once a de-identified rare or specialty disease patient is uncovered, IPM.ai enables clients to reach their top physicians directly, so they can prescribe a treatment-appropriate therapy or recommend a clinical trial. 

Fisher also discusses how IPM.ai works in cooperation with its sister organization, Swoop, to help reach and activate patient and physician audiences through healthcare advertising and a next best action engagement model, including for rare and specialty disorders.

Ai is an outstanding tool to help advance medical and business aspirations.

In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, a division of Real Chemistry, explains how weekly data from 300 million patients can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes.
Machine learning and artificial intelligence have emerged as key technologies for stitching together medical events and then predicting a diagnosis, even for conditions that are so rare no ICD-10 code exists. Once a de-identified rare or specialty disease patient is uncovered, IPM.ai enables clients to reach their top physicians directly, so they can prescribe a treatment-appropriate therapy or recommend a clinical trial. 
Fisher also discusses how IPM.ai works in cooperation with its sister organization, Swoop, to help reach and activate patient and physician audiences through healthcare advertising and a next best action engagement model, including for rare and specialty disorders.
Ai is an outstanding tool to help advance medical and business aspirations.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;